APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment-Reference-Cited by-同舟云学术

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Published:2016-06-23 Issue:25 Volume:127 Page:3225-3236
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tai Yu-Tzu¹²,Acharya Chirag¹,An Gang¹,Moschetta Michele¹,Zhong Mike Y.¹,Feng Xiaoyan¹,Cea Michele¹,Cagnetta Antonia¹,Wen Kenneth¹,van Eenennaam Hans³,van Elsas Andrea³,Qiu Lugui⁴,Richardson Paul¹²,Munshi Nikhil¹²,Anderson Kenneth C.¹²

Affiliation:

1. The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Medicine, Harvard Medical School, Boston, MA;

3. Aduro Biotech Europe (formerly known as BioNovion), Oss, The Netherlands; and

4. Department of Lymphoma & Myeloma, Tianjin Cord Blood Bank, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Abstract

Key Points APRIL/BCMA activation promotes MM proliferation, survival, and immunosuppression in vitro and in vivo. Targeting the APRIL/BCMA pathway represents a promising mechanism-based immunotherapy to target MM and overcome drug resistance.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/25/3225/1353743/3225.pdf

Reference75 articles.

1. Elotuzumab therapy for relapsed or refractory multiple myeloma.;Lonial;N Engl J Med,2015

2. Targeting CD38 with daratumumab monotherapy in multiple myeloma.;Lokhorst;N Engl J Med,2015

3. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib.;Nijhof;Clin Cancer Res,2015

4. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.;Jiang;Leukemia

5. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.;Palumbo;Expert Rev Hematol,2015

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma;Cancer Letters;2024-03

2. Identification of an angiogenesis-related risk score model for survival prediction and immunosubtype screening in multiple myeloma;Aging;2024-02-05

3. The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies;Current Tissue Microenvironment Reports;2024-02-03

4. New Biological Therapies for Multiple Myeloma;Annual Review of Medicine;2024-01-29

5. Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells;Blood Cancer Journal;2024-01-25